Cerebrospinal Fluid Prognostic Biomarkers In Multiple Sclerosis

Author:M Alba Mañé-Martínez
Volume Info:Volume 1 Issue 2
Article Information

Volume 1 Issue 2 , pages 27-31
Published Dec 2015


Department of Neurology, Joan XXIII University Hospital, Universitat Rovira i Virgili, Tarragona, Spain

Multiple Sclerosis Unit, Department of Neurology, Bellvitge University Hospital, Universitat de Barcelona, L’Hospitalet de Llobregat, Spain


Corresponding Author: amane.hj23.ics@gencat.cat


Multiple sclerosis (MS) is a chronic autoimmune and disabling disease affecting the central nervous system (CNS)
of unknown etiology. As a diagnostic marker for MS does not exist, prognostic biomarkers of disease severity
become clinically relevant. Several CSF biomarkers related to the pathogenesis of brain lesions of MS are displayed.
Neurofilament light protein, glial fibrillary acidic protein, and chitinase 3-like 1 protein are presented as future useful clinical markers in MS. Difficulties in performing and comparing studies of biomarkers in MS are discussed.



Multiple sclerosis, CHI3L1, GFAP, neurofilament, prognostic biomarkers, disability progression, YKL-40.



Keep up to date with our latest
articles and journals